TMO · 10-Q · 2026Q3 · Full report
Clinical Research and Services Demand
THERMO FISHER SCIENTIFIC INC. · 2026-10-30 · Importance 32 · Surprise 24 · Matches filing data
Laboratory Products and Biopharma Services’ third-quarter organic revenue growth was primarily due to the pharma services business, research and safety market channel, and clinical research business. For the first nine months, organic growth was primarily due to clinical research, research and safety, and pharma services. These demand drivers spanned the segment’s clinical research, pharma services, and research and safety market channel businesses.
Key facts
- In the first nine months of 2026, Thermo Fisher Scientific Inc.’s clinical research business grew approximately $1.05 billion, contributing 6 percentage points of reported segment growth, primarily due to the Clario acquisition. source
- In the third quarter of 2026, Thermo Fisher Scientific Inc.’s clinical research business grew $425 million, contributing 7 percentage points of reported segment growth, primarily due to the Clario acquisition. source
- In the first nine months of 2026, Thermo Fisher Scientific Inc.’s pharma services business grew $539 million and its research and safety market channel grew $422 million, contributing 3 and 2 percentage points, respectively, of reported segment growth. source
- In the third quarter of 2026, Thermo Fisher Scientific Inc.’s pharma services business grew $306 million and its research and safety market channel grew $169 million, contributing 5 and 3 percentage points, respectively, of reported segment growth. source
- In the third quarter of 2026, Thermo Fisher Scientific Inc.’s Laboratory Products and Biopharma Services organic revenue increase was primarily due to growth in pharma services, the research and safety market channel, and clinical research. source
- In the first nine months of 2026, Thermo Fisher Scientific Inc.’s Laboratory Products and Biopharma Services organic revenue increase was primarily due to clinical research, the research and safety market channel, and pharma services. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +8.7% | In the first nine months of 2026, Thermo Fisher Scientific Inc.’s clinical research business grew approximately $1.05 billion,… |